![]() |
|
---|---|
Systematic (IUPAC) name | |
(1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate | |
Clinical data | |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a607007 |
Pregnancy cat. | ? |
Legal status | Withdrawn from market |
Routes | Oral |
Identifiers | |
CAS number | 116644-53-2 ![]() |
ATC code | C08CX01 |
PubChem | CID 60662 |
DrugBank | DB01388 |
UNII | 27B90X776A ![]() |
KEGG | D08217 ![]() |
ChEMBL | CHEMBL45816 ![]() |
Chemical data | |
Formula | C29H38FN3O3 |
Mol. mass | 495.63 g/mol |
![]() |
Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.
It is nonselective.[1]
On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market,[2] due to the potential for drug interactions, some of them serious, which may occur when it is taken together with some other medications.
![]() |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |